Loading stock…

Teladoc Health, Inc. (TDOC) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Teladoc Health, Inc.

TDOCMarket cap $1.05BPrice $5.8

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Tech

Connects patients with doctors through virtual visits, mental health support, and chronic condition management, all from a smartphone. It's the largest telehealth provider in the U.S., yet still hasn't turned a consistent profit.

In Bastion Portfolios?

52W Return-32%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+2%3

Revenue Forecast

Rev CAGR (1y)-5%1

Rev CAGR (3y)-2%1

Rev CAGR (5y)+0%1

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Margin-6%1

Net Income Margin-7%1

Free Cash Flow Margin10%6

Debt

Net Debt/EBITDA3.43

Efficiency

ROE-13%1

ROA-6%1

Earnings Stabilityna–

GEAR+VERY WEAK2

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BV0.810

EV Multiples

EV/EBITDA Fwd510

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield24.2%10

Dividend Yieldna–

Momentum

Short term

1 month return-8%3

3 month return-39%1

YTD return-18%2

Mid term

Price vs 52wHigh58%2

1 year return-31%2

Long term

3 year return-69%1

5 year return-96%1

Risk Shield

Price Risk

Beta1.71

Volatility64%2

Free Cash Flow

Free Cash Flow Margin10%6

Free Cash Flow Yield24.2%10

Quality

ROCE-8%1

Earnings Stabilityna–

Net Debt/EBITDA3.43

02Growth

Is it actually growing, and how fast?

TDOCTeladoc Health

Revenue FY25$2.5B

GROWTH RATING↗

VERY WEAK2 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+2%3

Revenue, next 1Y-5%1

Revenue, next 3Y, CAGR-2%1

Revenue, next 5Y, CAGR+0%1

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Growth is the weak spot here, trailing 98% of companies worldwide.

Revenue grew 2%/yr over the last 3 years, behind 70% of companies worldwide.3/10

Revenue is set to shrink 2%/yr over the next 3 years, behind most of the market.1/10

Revenue grew 2%/yr over the last 3 years, but it is set to shrink 2%/yr from here.

Over five years revenue is set to hold flat, behind 90% of companies worldwide.1/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business heading into decline. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK3 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-8%3

3-month return-39%1

YTD return-18%2

MID & LONG-TERM▾SCORE

% of 52-week high58%2

1-year return-31%2

3-year return-69%1

5-year return-96%1

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-69% over three years and -96% over five), behind 90% of the market.

It's down 31% over the past year, now 42% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-8%), over three months (-39%) and so far this year (-18%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Teladoc Health, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

TDOCTeladoc Health

Revenue FY25$2.5B

GROWTH RATING↗

VERY WEAK2 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+2%3

Revenue, next 1Y-5%1

Revenue, next 3Y, CAGR-2%1

Revenue, next 5Y, CAGR+0%1

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Growth is the weak spot here, trailing 98% of companies worldwide.

Revenue grew 2%/yr over the last 3 years, behind 70% of companies worldwide.3/10

Revenue is set to shrink 2%/yr over the next 3 years, behind most of the market.1/10

Revenue grew 2%/yr over the last 3 years, but it is set to shrink 2%/yr from here.

Over five years revenue is set to hold flat, behind 90% of companies worldwide.1/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business heading into decline. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK3 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-8%3

3-month return-39%1

YTD return-18%2

MID & LONG-TERM▾SCORE

% of 52-week high58%2

1-year return-31%2

3-year return-69%1

5-year return-96%1

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-69% over three years and -96% over five), behind 90% of the market.

It's down 31% over the past year, now 42% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-8%), over three months (-39%) and so far this year (-18%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Teladoc Health, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community